Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
15.38
-0.07 (-0.45%)
At close: Aug 1, 2025, 4:00 PM
15.43
+0.05 (0.33%)
After-hours: Aug 1, 2025, 7:54 PM EDT

Nordstrom Statistics

Total Valuation

Teva Pharmaceutical has a market cap or net worth of $17.64 billion. The enterprise value is $33.02 billion.

Market Cap17.64B
Enterprise Value 33.02B

Important Dates

The last earnings date was Wednesday, July 30, 2025, before market open.

Earnings Date Jul 30, 2025
Ex-Dividend Date n/a

Share Statistics

Teva Pharmaceutical has 1.15 billion shares outstanding. The number of shares has increased by 1.25% in one year.

Current Share Class n/a
Shares Outstanding 1.15B
Shares Change (YoY) +1.25%
Shares Change (QoQ) +0.17%
Owned by Insiders (%) 0.42%
Owned by Institutions (%) 78.48%
Float 1.14B

Valuation Ratios

PE Ratio n/a
Forward PE 5.90
PS Ratio 1.05
Forward PS 1.32
PB Ratio 2.58
P/TBV Ratio n/a
P/FCF Ratio 19.82
P/OCF Ratio 12.69
PEG Ratio 0.84
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.30, with an EV/FCF ratio of 37.11.

EV / Earnings n/a
EV / Sales 1.99
EV / EBITDA 7.30
EV / EBIT 9.44
EV / FCF 37.11

Financial Position

The company has a current ratio of 1.06, with a Debt / Equity ratio of 2.57.

Current Ratio 1.06
Quick Ratio 0.48
Debt / Equity 2.57
Debt / EBITDA 3.76
Debt / FCF 19.71
Interest Coverage 3.59

Financial Efficiency

Return on equity (ROE) is -2.42% and return on invested capital (ROIC) is 8.77%.

Return on Equity (ROE) -2.42%
Return on Assets (ROA) 5.37%
Return on Invested Capital (ROIC) 8.77%
Return on Capital Employed (ROCE) 12.38%
Revenue Per Employee $451,480
Profits Per Employee -$4,263
Employee Count36,830
Asset Turnover 0.41
Inventory Turnover 2.26

Taxes

In the past 12 months, Teva Pharmaceutical has paid $94.00 million in taxes.

Income Tax 94.00M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -11.76% in the last 52 weeks. The beta is 0.60, so Teva Pharmaceutical's price volatility has been lower than the market average.

Beta (5Y) 0.60
52-Week Price Change -11.76%
50-Day Moving Average 16.85
200-Day Moving Average 17.28
Relative Strength Index (RSI) 35.20
Average Volume (20 Days) 12,391,498

Short Selling Information

Short Interest 53.42M
Short Previous Month 40.00M
Short % of Shares Out 4.68%
Short % of Float n/a
Short Ratio (days to cover) 5.24

Income Statement

In the last 12 months, Teva Pharmaceutical had revenue of $16.63 billion and -$157.00 million in losses. Loss per share was -$0.14.

Revenue16.63B
Gross Profit 8.25B
Operating Income 3.50B
Pretax Income 131.00M
Net Income -157.00M
EBITDA 4.52B
EBIT 3.50B
Loss Per Share -$0.14
Full Income Statement

Balance Sheet

The company has $2.16 billion in cash and $17.54 billion in debt, giving a net cash position of -$15.38 billion or -$13.41 per share.

Cash & Cash Equivalents 2.16B
Total Debt 17.54B
Net Cash -15.38B
Net Cash Per Share -$13.41
Equity (Book Value) 6.83B
Book Value Per Share 5.95
Working Capital 759.00M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $1.39 billion and capital expenditures -$500.00 million, giving a free cash flow of $890.00 million.

Operating Cash Flow 1.39B
Capital Expenditures -500.00M
Free Cash Flow 890.00M
FCF Per Share $0.78
Full Cash Flow Statement

Margins

Gross margin is 49.60%, with operating and profit margins of 21.05% and -0.94%.

Gross Margin 49.60%
Operating Margin 21.05%
Pretax Margin -0.41%
Profit Margin -0.94%
EBITDA Margin 27.20%
EBIT Margin 21.05%
FCF Margin 5.35%

Dividends & Yields

Teva Pharmaceutical does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -1.25%
Shareholder Yield -1.25%
Earnings Yield -0.89%
FCF Yield 5.04%
Dividend Details

Analyst Forecast

The average price target for Teva Pharmaceutical is $24.71, which is 60.66% higher than the current price. The consensus rating is "Strong Buy".

Price Target $24.71
Price Target Difference 60.66%
Analyst Consensus Strong Buy
Analyst Count 7
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on July 1, 2004. It was a forward split with a ratio of 2:1.

Last Split Date Jul 1, 2004
Split Type Forward
Split Ratio 2:1

Scores

Teva Pharmaceutical has an Altman Z-Score of 0.57 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 0.57
Piotroski F-Score 6